glp 1 compounded medications FDA says that the GLP-1 shortage is over Little Drugs - Agile Telehealth

Substantial heterogeneity was noted (I = 98%), meaning the evidence base is limited and inconsistent

(2017) Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice

If you're using it solely for weight management under medical supervision (like the programs we offer at TrimrX) and you are otherwise healthy, you are generally in the clear

doi:10.1016/j.neuint.2019.04.006 37

doi: 10.2174/0115734021398680251001102514 40

The agency also emphasised that the medication alone would not reverse the trend in obesity, which it recognised as a complex, chronic disease and a major driver of non-communicable diseases, including cardiovascular disease, type-2 diabetes and some types of cancer